Previous Close | 6.77 |
Open | 6.80 |
Bid | 6.45 |
Ask | 6.55 |
Strike | 160.00 |
Expire Date | 2025-01-17 |
Day's Range | 6.50 - 7.10 |
Contract Range | N/A |
Volume | |
Open Interest | 6.79k |
JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. It remains to be seen if MedTech sales improved.
As part of the strategic re-prioritization, JNJ terminates the phase II field study on mosnodenvir for the prevention of the dengue virus.
We recently compiled a list of the Best Stocks to Buy According to Billionaire Ray Dalio. In this article, we will look at where Johnson & Johnson (NYSE:JNJ) ranks among the best stocks to buy according to billionaire Ray Dalio. Ray Dalio was born in 1949 and graduated from Long Island University in 1971. After […]